As medical manager in Impact Tuberculosis / Access to Medicines at sanofi-aventis, I am fully involved in activites for the improvement of TB treatment, more specifically with the new development of rifapentine-based regimen for treatment shortening of tuberculosis. I am convince that a collaborative effort is essential for the rapid availibility of improved TB regimen.